View All Spotlights
DECLARE - Clinical Trial Spotlight
Stephen Wiviott, MD: Changes in the Treatment of Type 2 Diabetes
Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.
Stephen Wiviott, MD: Strengths and Limitations of the DECLARE-TIMI 58 Trial
Strengths of the DECLARE-TIMI 58 trial included a large primary prevention population, while the nature of the study meant that adherence was likely higher than it would be in a standard setting.
Dapagliflozin Reduces Heart Failure in Primary Prevention Population
The study showed noninferiority with relation to major adverse cardiovascular events and a reduction of heart failure, though no difference in cardiovascular death compared to placebo. There appear to be renal benefits to dapagliflozin as well.
Cirrhosis-Related Death Risk Lowered with Physical Activity
Treating Hepatitis C Linked to Reduced Parkinsonism
Peanut Allergy Drug Receives September FDA Decision Date
Cholesterol Levels Rise After a 24-Hour Fast
Reena Mehra, MD, MS: The State of Sleep Apnea
Affordable Care Act
PHYSICIAN'S MONEY DIGEST >
MD Magazine Resources
Terms & Conditions
Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.